eloralintide and tirzepatide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 16 Oct 2026: Trial started, NCT07881458
  2. 19 Oct 2026: Trial registered, NCT07881458

The trials

NCT06916065: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

State
Completed
Phase
Phase 1
People
188 taking part
Started
9 Apr 2025
Primary completion
19 Jan 2026
Arms
Eloralintide and Tirzepatide-Cohorts A-D
Results
None posted
  1. 8 Apr 2025: Trial registered
  2. 9 Apr 2025: Trial started
  3. 19 Jan 2026: Trial completed

NCT07881432: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

State
Not started
Phase
Phase 3
People
2,115 planned
Started
Dec 2026
Primary completion
Oct 2029
Arms
EloraTZP Dose 1, EloraTZP Dose 2, EloraTZP Dose 3, EloraTZP Dose 4, EloraTZP Dose 5
Results
None posted
  1. 19 Oct 2026: Trial registered

NCT07881458: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

State
Under way
Phase
Phase 3
People
1,000 planned
Started
16 Oct 2026
Primary completion
Oct 2029
Arms
EloraTZP
Results
None posted
  1. 16 Oct 2026: Trial started
  2. 19 Oct 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.